Patel Bhuvic, Desai Rupen, Pugazenthi Sangami, Butt Omar H, Huang Jiayi, Kim Albert H
Department of Neurological Surgery, Washington University School of Medicine, St. Louis, MO, United States.
Department of Medicine, Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO, United States.
Front Oncol. 2022 Mar 23;12:851758. doi: 10.3389/fonc.2022.851758. eCollection 2022.
Meningiomas are common primary central nervous system tumors derived from the meninges, with management most frequently entailing serial monitoring or a combination of surgery and/or radiation therapy. Although often considered benign lesions, meningiomas can not only be surgically inaccessible but also exhibit aggressive growth and recurrence. In such cases, adjuvant radiation and systemic therapy may be required for tumor control. In this review, we briefly describe the current WHO grading scale for meningioma and provide demonstrative cases of treatment-resistant meningiomas. We also summarize frequently observed molecular abnormalities and their correlation with intracranial location and recurrence rate. We then describe how genetic and epigenetic features might supplement or even replace histopathologic features for improved identification of aggressive lesions. Finally, we describe the role of surgery, radiotherapy, and ongoing systemic therapy as well as precision medicine clinical trials for the treatment of recurrent meningioma.
脑膜瘤是起源于脑膜的常见原发性中枢神经系统肿瘤,其治疗通常需要进行连续监测,或采用手术和/或放射治疗相结合的方式。尽管脑膜瘤通常被认为是良性病变,但它们不仅可能无法通过手术切除,而且还可能表现出侵袭性生长和复发。在这种情况下,可能需要辅助放疗和全身治疗来控制肿瘤。在本综述中,我们简要描述了当前世界卫生组织(WHO)的脑膜瘤分级标准,并提供了治疗抵抗性脑膜瘤的示范病例。我们还总结了常见的分子异常及其与颅内位置和复发率的相关性。然后,我们描述了基因和表观遗传特征如何补充甚至取代组织病理学特征,以更好地识别侵袭性病变。最后,我们描述了手术、放疗和正在进行的全身治疗的作用,以及精准医学临床试验在复发性脑膜瘤治疗中的应用。